# BEACON-1 (NCT07193511)

> BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

No report yet. It can be ordered.

- Drugs tested: AVZO-103
- Indication: locally advanced or metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07193511
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Avenzo Therapeutics, Inc.
- Conditions: Solid Tumor Cancer; Locally Advanced; Metastatic Solid Tumors; Urothelial Cancer
- Interventions: AVZO-103; Combination Agent
- Enrollment: 355
- Primary outcome: Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)
- Primary outcome: Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1)
- Primary outcome: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1)
- Primary outcome: Objective Response Rate (ORR) (Phase 2)

## Indexed commentary on BEACON-1 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=beacon-1-nct07193511
